Clinical trials: Obese Subjects
Overweight/Obesity
The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution
The study is being conducted to evaluate the bioequivalence between a single-dose pen and a multi-dose pen of HRS9531 injection solution.
- Trial name
- NCT06792955
- Testing
- HRS9531 injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity & Overweight
Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults
Muscle loss during caloric restriction is a significant concern for metabolic health and physical function, yet there is limited evidence on interventions that simultaneously target multiple contributing pathways.
- Trial name
- Redefine (NCT07447843)
- Testing
- Redefine
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Nature's Sunshine Products, Inc.
Otherwise Healthy Overweight or Obese
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled multiple-ascending dose (MAD) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of PHP-303 in otherwise healthy overweight or obese…
- Trial name
- NCT03775278
- Testing
- PHP-303
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- pH Pharma
Healthy Subjects;Overweight or Obesity
A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants
This trial is conducted in China. This study plans to include 2 parts, i.e., a single-dose study and a multiple-dose study: The single-dose study will be conducted in healthy adult participants to evaluate the safety…
- Trial name
- NCT07784699
- Testing
- GZC8072 Tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Metabolism and Nutrition Disorder, Obesity
A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.
This trial is conducted in Europe. The aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.
- Trial name
- NCT02717858
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Novo Nordisk A/S
Nicotine Dependence, Overweight
A Study of Naltrexone SR/ Bupropion SR in Overweight and Obese Subjects Who Are Nicotine-Dependent
The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in the treatment of nicotine-dependence in overweight and obese subjects.
- Conditions
- Nicotine Dependence, Overweight, Obesity
- Trial name
- NCT00563563
- Testing
- NB32, Ancillary therapy
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Orexigen Therapeutics, Inc
Subcutaneous Fat Disorder
Safety and Efficacy Study of 10XB-101 in Adults With Bilateral Flank Adiposity
The goal of this clinical trial is to test the safety and effectiveness of an injection study drug in decreasing bilateral flank adiposity.
- Trial name
- NCT05760248
- Testing
- 10XB-101 Solution for Injection, 6.0%
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- 10xBio, LLC
Obesity
A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants
This is a Phase 1, randomized, blinded, placebo-controlled study in up to approximately 51 non-diabetic obese participants with a body mass index (BMI) ≥ 35 kg/m^2.
- Trial name
- NCT03625778
- Testing
- MEDI0382
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- MedImmune LLC
Nonalcoholic Steatohepatitis (NASH)
A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)
An Open-Label Part was added: This part will enroll in selected sites which are less affected by the COVID-19 pandemic. 150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups…
- Trial name
- ARMOR (NCT04104321)
- Testing
- Aramchol free acid
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- Galmed Research and Development, Ltd.
Obesity
Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.
The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
- Trial name
- NCT00396448
- Testing
- CP-945,598 Treatment B, CP-945,598 Treatment A
- Where
- 61 sites in United States, Argentina and 9 more
- Volunteers
- 1,253 people
- Sponsor
- Pfizer
Obesity
A Phase 1b Study to Evaluate the Safety of XEN-101
This Phase 1b study will evaluate the effects of XEN-101 in subjects with obesity
- Trial name
- NCT06417697
- Testing
- XEN-101
- Where
- Australia
- Volunteers
- 33 people
- Sponsor
- Xeno Biosciences
Obesity, Overweight
A Safety and Efficacy Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects
The purpose of this study is to determine whether the combination of naltrexone SR and bupropion SR is safe and effective in the treatment of obesity.
- Trial name
- NCT00567255
- Testing
- Naltrexone SR 32 mg/bupropion SR 360 mg/day, Ancillary therapy
- Where
- 36 sites in United States
- Volunteers
- 1,496 people
- Sponsor
- Orexigen Therapeutics, Inc
Metabolism and Nutrition Disorder, Obesity
Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers
This trial will be conducted in the United States of America (USA). The aim of this clinical trial is to investigate whether NNC 0070-0002-0349 is safe and well tolerated.
- Trial name
- NCT00728455
- Testing
- NNC 0070-0002-0349
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Obesity
A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years
This trial is conducted in Europe. The purpose of the trial is to assess safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of liraglutide in obese adolescent subjects aged 12 to 17 years.
- Trial name
- NCT01789086
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
Primary Objective: To assess in overweight to obese subjects the change in sleep energy expenditure after repeated subcutaneous (SC) doses of SAR425899.
- Trial name
- NCT03376802
- Testing
- SAR425899
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi
Overweight, Diabetes
Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects w/o Type 2 Diabetes
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects without or with Type 2 Diabetes
- Conditions
- Overweight, Diabetes, PreDiabetes, Obesity
- Trial name
- LIGHT-UP (NCT03058029)
- Testing
- Gelesis200
- Where
- 30 sites in United States, Canada and 6 more
- Volunteers
- 300 people
- Sponsor
- Gelesis, Inc.
Diabetes Mellitus, Type 2, Obesity
Pharmacodynamic Study of the Effect of INCB013739 on Insulin Sensitivity in Obese, Type 2 Diabetic Subjects
Purpose: A 28-day US study in patients with type 2 diabetes mellitus to assess the safety and tolerability as well as the effects of treatment with an investigational drug.
- Trial name
- NCT00478322
- Testing
- INCB013739
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Obesity, Over-weight
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for certain doses of beloranib in obese subjects with Prader-Willi Syndrome.
- Conditions
- Obesity, Over-weight, Prader-Willi Syndrome
- Trial name
- NCT01818921
- Testing
- ZGN-440 sterile diluent, 1.2 mg ZGN-440 for injectable suspension, 1.8 mg ZGN-440 for injectable suspension
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Zafgen, Inc.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent
This trial is conducted in the United States of America (USA). The aim of this trial is to determine the dose-response relationship for body weight and five escalating doses of NNC 90-1170 (liraglutide) in subjects with type 2…
- Trial name
- NCT01511198
- Testing
- liraglutide, metformin
- Where
- 39 sites in United States
- Volunteers
- 223 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period
Primary Objectives: Main study: To assess in overweight to obese subjects and type 2 diabetes mellitus (T2DM) patients not requiring anti-diabetic pharmacotherapy the safety and tolerability of 3 different dose escalation…
- Trial name
- NCT03414736
- Testing
- SAR425899
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sanofi